HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website is currently a joint development effort by CHDI and UCLA, through the laboratory of Dr. Giovanni Coppola. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Want to learn more about HDinHD?
Watch a detailed video overview of HDinHD presented at the 16th Annual HD Therapeutics Conference (April 2021). The video outlines data resources and tools within HDinHD and provides a detailed demonstration of the new HD Explorer tool. |
Read the following publication introducing HDinHD: HDinHD: A Rich Data Portal for Huntington’s Disease Research, J Huntingtons Dis., 10, 405-412
Latest news and publications from around the HD Ecosystem
Literature
- More than just a number: the gut microbiota and brain function across the extremes of life
- Copper homeostasis and cuproptosis in central nervous system diseases
- Apathy and Functional Status in Early-Stage Huntington's Disease
- Break-up and recovery of harmony between direct and indirect pathways in the basal ganglia: Huntington's disease and treatment
- Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca<sup>2+</sup> and Mg<sup>2+</sup> in the formulation
News
- SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Strategic Shifts
- AI Adoption Trends: AI Agents Being Given Money To Spend, AI M&A Fueling Corporate Strategy
- Copper homeostasis and cuproptosis in central nervous system diseases - Nature
- Newamsterdam's obicetrapib combo nails phase III LDL-C endpoints | BioWorld
- Sage shuts down Huntington's program after phase II failure - BioWorld